Ashkenazi Jewish Screening in the Twenty-first Century
Overview
Authors
Affiliations
Ashkenazi Jewish genetic screening has expanded significantly in the past 4 decades. Individuals of Eastern European (Ashkenazi) Jewish (AJ) descent are at increased risk of having offspring with particular genetic diseases that have significant morbidity and mortality. In addition, there are some disorders, such as cystic fibrosis, for which northern European Caucasians are at comparable risk with those of an AJ background. Carrier screening for many of these Jewish genetic disorders has become standard of care. As technology advances, so does the number of disorders for which screening is available. Thus, we need to continue to be cognizant of informed consent, test sensitivity, confidentiality, prenatal diagnosis, preimplantation genetic screening, and public health concerns regarding testing.
Cellular and molecular mechanisms of aspartoacylase and its role in Canavan disease.
Gronbaek-Thygesen M, Hartmann-Petersen R Cell Biosci. 2024; 14(1):45.
PMID: 38582917 PMC: 10998430. DOI: 10.1186/s13578-024-01224-6.
Brace S, Diekmann Y, Booth T, Macleod R, Timpson A, Stephen W Curr Biol. 2022; 32(20):4350-4359.e6.
PMID: 36044903 PMC: 10499757. DOI: 10.1016/j.cub.2022.08.036.
Barlow-Stewart K, Bardsley K, Elan E, Fleming J, Berman Y, Fleischer R J Community Genet. 2021; 13(1):121-131.
PMID: 34846685 PMC: 8799788. DOI: 10.1007/s12687-021-00567-8.
A collaborative genetic carrier screening model for the British Ashkenazi Jewish community.
Ziff M, Harris J J Community Genet. 2021; 13(1):133-135.
PMID: 34841494 PMC: 8627906. DOI: 10.1007/s12687-021-00568-7.
Fan C, Castonguay L, Rummell S, Levesque S, Mitchell J, Sillon G J Genet Couns. 2017; 27(2):426-438.
PMID: 28791521 DOI: 10.1007/s10897-017-0133-4.